- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03431142
Optimal antiPlatelet Therapy for High Bleeding and Ischemic RISK Patients Trial (OPT-BIRISK)
Extended Antiplatelet Therapy With Clopidogrel Alone Versus Clopidogrel Plus Aspirin After Completion of 9- to 12-month Dual Antiplatelet Therapy for ACS Patients With Both High Bleeding and Ischemic Risk.
Current guidelines recommend that patients with ACS undergoing stent implantation might be offered extended DAPT treatment for up to 30 months if necessary.
Therefore, we designed a prospective, multicenter, randomized, placebo-controlled trial among ACS patients with high-risk on ischemic and bleeding who received a new generation of DES and received 9 to 12 months of DAPT, and evaluated whether clopidogrel monotherapy reduce the risk of bleeding compared with clopidogrel plus ASA in the following 9 months and achieved non-inferior outcomes in preventing ischemic risk.
Study Overview
Status
Intervention / Treatment
Detailed Description
Current guidelines recommend that patients with ACS undergoing stent implantation might be offered extended DAPT treatment for up to 30 months if necessary. For patients with high risk of both ischemic and hemorrhage, despite prolonged use of DAPT may bring antithrombotic benefit, it may also increase the risk of bleeding. There is an urgent need for specific guiding on intensive antiplatelet therapy in this population of patients to reduce the risk of ischemia and to avoid the risk of bleeding.
Previous studies have shown that, after 12 months of DAPT treatment, continuation of clopidogrel monotherapy may further reduce the risk of ischemia and bleeding compared with aspirin. Therefore, we designed a prospective, multicenter, randomized, placebo-controlled trial among ACS patients with high-risk on ischemic and bleeding who received a new generation of DES and received 9 to 12 months of DAPT, and evaluated whether clopidogrel monotherapy reduce the risk of bleeding compared with clopidogrel plus ASA in the following 9 months and achieved non-inferior outcomes in preventing ischemic risk.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Liaoning
-
Shenyang, Liaoning, China, 110016
- Recruiting
- General Hospital of Shenyang Military Region
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ACS patients undergoing PCI (New-Generation DES) and finishing 9-12 months of DAPT
- 18 ~ 85 years old adult patients
- Patients under the age of 65 must meet at least one of the following clinical criteria of high bleeding risk and at least one of the following clinical criteria of high ischemic risk; Patients aged 65-75 must meet one of the following clinical criteria of either high bleeding risk or high ischemic risk.
Clinical criteria of high bleeding risk:
- ≥75 years old
- female
- Iron deficiency anemia
- history of stroke (hemorrhagic or ischemic)
- ongoing medical treatment of diabetes (oral hypoglycemic agents or subcutaneous insulin)
- Chronic kidney disease (eGFR <60mL/min or creatinine clearance<60mL/min)
Clinical criteria of high ischemic risk:
- ≥75 years old
- Multiple coronary lesions
- target lesions required for stent of total length> 30mm
- Thrombotic target lesions
- Bifurcation lesions are Medina 0, 1, 1 or 1, 1, and 1, with stents implanted in both main branch and side branch
- Left main coronary artery (≥50%) or proximal LAD (≥70%) lesions
- Calcified plaques requiring endovascular excision
- acute coronary syndrome with troponin positive
- Previous myocardial infarction, ischemic stroke, diagnosed peripheral arterial disease (PAD), or revascularization due to coronary artery disease (CAD) / PAD
- recurrent myocardial infarction, revascularization, stent thrombosis, stroke in the last 9 months
- ongoing medical treatment of diabetes (oral hypoglycemic agents or subcutaneous insulin)
- Chronic kidney disease (eGFR<60 mL/min or creatinine clearance <60 mL/min)
Exclusion Criteria:
- Discontinuation or termination of DAPT treatment during the past 6 months due to adverse events (bleeding or ischemia) or other conditions
- Surgery plan within 90 days
- Coronary Revascularization (Surgical or Intervention) Program within 90 days
- Dialysis-dependent renal failure
- Moderate or severe hepatic insufficiency (2 times the upper limit of normal for ALT or AST)
- Life expectancy <1 year
- Unable or unwilling to provide informed consent
- Women with childbearing potential
- Platelet count <100000/mm3
- Subjects undergoing warfarin or similar anticoagulant therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Clopidogrel monotherapy
On the basis of 9-12 months of DAPT(aspirin+clopidogrel), continue clopidogrel monotherapy in the following 9 months.
|
Additional 9 months of clopidogrel monotherapy after 9-12 months of DAPT (aspirin+clopidogrel)
|
ACTIVE_COMPARATOR: Clopidogrel plus aspirin
On the basis of 9-12 months of DAPT(aspirin+clopidogrel), continue DAPT (aspirin+clopidogrel) in the following 9 months.
|
Additional 9 months of clopidogrel plus aspirin after 9-12 months of DAPT (aspirin+clopidogrel)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical relevant bleeding events
Time Frame: During 9-month follow up
|
defined as BARC type 2-5 bleeding events
|
During 9-month follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All bleeding events
Time Frame: During 9-month follow up
|
defined all BARC type 1-5 bleeding events
|
During 9-month follow up
|
Major adverse cardiovascular and cerebrovascular events(MACCE)
Time Frame: During 9-month follow up
|
defined as a composite endpoints of all-cause death, myofarction, stroke and clinically indicated revascularization
|
During 9-month follow up
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Ischemia
- Hemorrhage
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Aspirin
- Clopidogrel
Other Study ID Numbers
- CLOPIL08732
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prolonged DAPT in ACS Patients With Hisk of Both Ischemic and Hemorrhage
-
University Hospital, BordeauxRecruitingCardiac Rehabilitation Program Following the Management of ACS in Patients Presenting With SCADFrance
-
HealthPartners InstituteCompletedHemorrhage | Acute Bleeding on Long-Term Anticoagulation Therapy | Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time) | Urgent Reversal of Vitamin K Antagonist (VKA) AnticoagulationUnited States
-
Assiut UniversityUnknownAll Patients With Ischemic Cerebrovascular Stroke Aged ≥18 Years of Both Sex
-
The First Hospital of Hebei Medical UniversityCompletedThe Levels of Cerebral Perfusion and Collateral Circulation in Patients With Subacute StrokeChina
Clinical Trials on Clopidogrel
-
Korea University Anam HospitalCompleted
-
Chinese PLA General HospitalUnknownCLOPIDOGREL, POOR METABOLISM of (Disorder)China
-
Ospedale San DonatoCompletedAcute Myocardial InfarctionItaly
-
University of PecsTerminatedStable Angina Pectoris | Ad Hoc Percutaneous Coronary InterventionHungary
-
Hospital Central San Luis Potosi, MexicoUnknownAcute Coronary Syndrome
-
University of North Carolina, Chapel HillCompleted
-
Lady Reading Hospital, PakistanPakistan Chest Society, PakistanRecruitingCOPD | COPD Exacerbation AcutePakistan
-
Deutsches Herzzentrum MuenchenTerminatedCoronary Artery DiseaseGermany
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaCompleted
-
University of PecsHungarian Academy of Sciences; KRKACompletedCoronary Heart Disease | Percutaneous Coronary Intervention